# A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

> **NCT03858634** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 58 (actual)

## Conditions studied

- Chronic Idiopathic Urticaria
- Chronic Idiopathic Pruritus
- Lichen Planus
- Lichen Simplex Chronicus
- Plaque Psoriasis

## Interventions

- **DRUG:** KPL-716
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03858634
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-29
- **Primary completion:** 2020-04-01
- **Final completion:** 2020-06-08
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03858634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03858634, "A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT03858634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*